102 related articles for article (PubMed ID: 21273026)
1. Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis HMGA2 as a prognostic marker of bladder cancer.
Yang GL; Zhang LH; Bo JJ; Hou KL; Cai X; Chen YY; Li H; Liu DM; Huang YR
Eur J Surg Oncol; 2011 Mar; 37(3):265-71. PubMed ID: 21273026
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy.
Chen W; Luo JH; Hua WF; Zhou FJ; Lin MC; Kung HF; Zeng YX; Guan XY; Xie D
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):400-8. PubMed ID: 19155439
[TBL] [Abstract][Full Text] [Related]
3. HMGA2 overexpression in non-small cell lung cancer.
Meyer B; Loeschke S; Schultze A; Weigel T; Sandkamp M; Goldmann T; Vollmer E; Bullerdiek J
Mol Carcinog; 2007 Jul; 46(7):503-11. PubMed ID: 17477356
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance.
Zhao ZS; Chu YQ; Ye ZY; Wang YY; Tao HQ
Hum Pathol; 2010 May; 41(5):686-96. PubMed ID: 20060156
[TBL] [Abstract][Full Text] [Related]
5. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment.
Liu HB; Kong CZ; Zeng Y; Liu XK; Bi JB; Jiang YJ; Han S
Urol Oncol; 2009; 27(3):277-83. PubMed ID: 18555709
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CDC91L1 (PIG-U) in bladder urothelial cell carcinoma: correlation with clinical variables and prognostic significance.
Shen YJ; Ye DW; Yao XD; Trink B; Zhou XY; Zhang SL; Dai B; Zhang HL; Zhu Y; Guo Z; Wu G; Nagpal J
BJU Int; 2008 Jan; 101(1):113-9. PubMed ID: 17941920
[TBL] [Abstract][Full Text] [Related]
7. HMGA2 expression in a canine model of prostate cancer.
Winkler S; Murua Escobar H; Meyer B; Simon D; Eberle N; Baumgartner W; Loeschke S; Nolte I; Bullerdiek J
Cancer Genet Cytogenet; 2007 Sep; 177(2):98-102. PubMed ID: 17854662
[TBL] [Abstract][Full Text] [Related]
8. Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours.
Franco R; Esposito F; Fedele M; Liguori G; Pierantoni GM; Botti G; Tramontano D; Fusco A; Chieffi P
J Pathol; 2008 Jan; 214(1):58-64. PubMed ID: 17935122
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
10. N-acetylglucosaminyltransferase V and beta1-6 branching N-linked oligosaccharides are associated with good prognosis of patients with bladder cancer.
Ishimura H; Takahashi T; Nakagawa H; Nishimura S; Arai Y; Horikawa Y; Habuchi T; Miyoshi E; Kyan A; Hagisawa S; Ohyama C
Clin Cancer Res; 2006 Apr; 12(8):2506-11. PubMed ID: 16638859
[TBL] [Abstract][Full Text] [Related]
11. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
12. HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer.
Fabjani G; Tong D; Wolf A; Roka S; Leodolter S; Hoecker P; Fischer MB; Jakesz R; Zeillinger R
Oncol Rep; 2005 Sep; 14(3):737-41. PubMed ID: 16077985
[TBL] [Abstract][Full Text] [Related]
13. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome.
Mylona E; Giannopoulou I; Diamantopoulou K; Bakarakos P; Nomikos A; Zervas A; Nakopoulou L
Eur J Surg Oncol; 2009 Feb; 35(2):197-201. PubMed ID: 18513919
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D3 expression in primary Ta/T1 bladder cancer.
Lopez-Beltran A; Requena MJ; Luque RJ; Alvarez-Kindelan J; Quintero A; Blanca AM; Rodriguez ME; Siendones E; Montironi R
J Pathol; 2006 May; 209(1):106-13. PubMed ID: 16482499
[TBL] [Abstract][Full Text] [Related]
16. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
17. XPC epigenetic silence coupled with p53 alteration has a significant impact on bladder cancer outcome.
Yang J; Xu Z; Li J; Zhang R; Zhang G; Ji H; Song B; Chen Z
J Urol; 2010 Jul; 184(1):336-43. PubMed ID: 20488473
[TBL] [Abstract][Full Text] [Related]
18. [Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance].
Liu CX; Wen Y; Xu K; Zheng SB; Xu YW; Chen BS
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1389-91, 1394. PubMed ID: 20584685
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of clusterin expression to prognosis of bladder carcinoma].
Luo JH; Xie D; Chen W; Dai YP; Li XF; Tao Y; Zheng KL
Ai Zheng; 2005 Jun; 24(6):743-7. PubMed ID: 15946493
[TBL] [Abstract][Full Text] [Related]
20. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
